Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome

Cornea

Volumn 27, Issue 1, 2008, Pages 70-73

  Uy, Harvey S ^a,b   Chan, Pik Sha ^a,b   Ang, Robert Edward ^a,b  

^a Asian Eye Institute   (Philippines)

^b UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

Author keywords

Bevacizumab; Neovascularization; Ocular surface disease; Stevens Johnson syndrome

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; ARTICLE; CASE REPORT; CORNEA NEOVASCULARIZATION; FEMALE; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; STEVENS JOHNSON SYNDROME; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CORNEAL NEOVASCULARIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 40449096035     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e318158f6ad     Document Type: Article

References (34)

1. Power WJ, Ghoraishi M, Lloves JM, et al. Analysis of the acute manifestations of erythema multiforme/Stevens-Johnson syndrome/.toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995;102: 1669-1676.
2. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Ophthalmology. 1994;101:1536-1547. (Pubitemid 24347052)
3. Wall V, Yen MT, Yang MC, et al. Management of the late ocular sequelae of Stevens-Johnson syndrome. Ocul Surf. 2003;1:192-201. (Pubitemid 41263894)
4. Kaido M, Dogru M, Yamada M, et al. Functional visual acuity in Stevens- Johnson syndrome. Am J Ophthalmol. 2006;142:917-922.
5. Kompella VB, Sangwan VS, Bansal AK, et al. Ophthalmic complications and management of Stevens-Johnson syndrome at a tertiary eye care center in south India. Indian J Ophthalmol. 2002;50:283-286. (Pubitemid 36019804)
6. Epstein RJ, Stulting RD, Hendricks RL, et al. Corneal neovascularization. Pathogenesis and inhibition. Cornea. 1987;6:250-257. (Pubitemid 18005952)
7. Shimazaki J, Aiba M, Goto E, et al. Transplantation of human limbal stem epithelium cultivated on amniotic membrane for the treatment of severe ocular surface disorders. Ophthalmology. 2002;109:1285-1290. (Pubitemid 34700919)
8. Solomon A, Espana EM, Tseng SC. Amniotic membrane transplantation for reconstruction of the conjunctival fornices. Ophthalmology. 2003;110: 93-100. (Pubitemid 36068732)
9. Gomes JA, Santos MS, Ventura AS, et al. Amniotic membrane with living related corneal limbal/conjunctival allograft for ocular surface reconstruction in Stevens-Johnson syndrome. Arch Ophthalmol. 2003;121: 1369-1374. (Pubitemid 37243736)
10. Kaido M, Goto E, Dogru M, et al. Punctal occlusion in the management of chronic Stevens-Johnson syndrome. Ophthalmology. 2004;111:895-900. (Pubitemid 38586681)
11. Nishida K, Yamato M, Hayashida Y, et al. Corneal reconstruction with tissue-engineered cell sheets composed of autologous oral mucosal epithelium. N Engl J Med. 2004;351:1170-1172.
12. Nakamura T, Inatomi T, Sotozono C, et al. Transplantation of cultivated autologous oral mucosal epithelial cells in patients with severe ocular surface disorders. Br J Ophthalmol. 2004;88:1280-1284. (Pubitemid 39312972)
13. Tseng SC, Di Pascuale MA, Liu DT, et al. Intraoperative mitomycin C and amniotic membrane transplantation for formix reconstruction in several cicatricial ocular surface diseases. Ophthalmology. 2005;112:896-903. (Pubitemid 40631512)
14. Nakamura T, Ang LP, Rigby H, et al. The use of autologous serum in the development of corneal and oral epithelial equivalents in patients with Stevens-Johnson syndrome. Invest Ophthalmol Vis Sci. 2006;47:909-916. (Pubitemid 46768321)
15. Hollick EJ, Watson SL, Dart JK, et al. Legeais BioKpro III keratoprosthesis implantation: long-term results in seven patients. Br J Ophthalmol. 2006;90:1146-1151. (Pubitemid 44351147)
16. Inatomi T, Nakamura T, Kojyo M, et al. Ocular surface reconstruction with combination of cultivated autologous oral mucosal epithelial transplantation and penetrating keratoplasty. Am J Ophthalmol. 2006; 142:757-764.
17. Santos MS, Gomes JA, Hofling-Lima AL, et al. Survival analysis of conjunctival limbal grafts and amniotic membrane transplantation in eyes with total limbal stem cell deficiency. Am J Ophthalmol. 2005;140:223-230.
18. Geerling G, Liu CS, Collin JR, et al. Costs and gains of complex procedures to rehabilitate end stage ocular surface disease. Br J Ophthalmol. 2002;86:1220-1221. (Pubitemid 35238596)
19. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249. (Pubitemid 32751680)
20. Joussen AM, Poulaki V, Mitsiades N, et al. VEGF-dependent conjunctivailization of the corneal surface. Invest Ophthalmol Vis Sci. 2003;44:117-123.
21. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45: 2666-2673. (Pubitemid 38998863)
22. Singh N, Higgins E, Amin S, et al. Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization. Cornea. 2007;26:65-72. (Pubitemid 46041566)
23. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047. (Pubitemid 40797459)
24. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335. (Pubitemid 41073112)
25. Miller J, Chung CY, Kim RY, MARINA Study Group. Randomized, controlled, phase III study of ranibizumab (Lucentis) for minimally classic or occult neovascular age-related macular degeneration. Program and abstracts of the American Society of Retina Specialists 23rd Annual Meeting, July 16-20, 2005, Montreal, Quebec, Canada.
26. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-807. (Pubitemid 46846656)
27. Epstein RJ, Hendricks RL, Harris DM. Photodynamic therapy for corneal neovascularization. Cornea. 1991;10:424-432.
28. Gohto Y, Obana A, Kanai M, et al. Treatment parameters for selective occlusion of experimental corneal neovascularization by photodynamic therapy using a water soluble photosensitizer, ATX-S10 (Na). Exp Eye Res. 2001;72:13-22. (Pubitemid 32056716)
29. Fossarello M, Peiretti E, Zucca I, et al. Photodynamic therapy of corneal neovascularization with vertiporfin. Cornea. 2003;22:485-488. (Pubitemid 36759046)
30. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for firstline metastatic colorectal cancer. J Clin Oncol. 2005;23:3502-3508.
31. Sotozono C, Ang LP, Koizumi N, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens- Johnson syndrome. Ophthalmology. 2007;114:1294-1302. (Pubitemid 47001496)
32. Kiss C, Michels S, Prager F, et al. Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina. 2006;26:877-881. (Pubitemid 44547439)
33. Feiner L, Barr EE, Ying-Bo S, et al. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina. 2006;26:882-888. (Pubitemid 44547440)
34. Puangsricharern V, Tseng SC. Cytologic evidence of corneal diseases with limbal stem cell deficiency. Ophthalmology. 1995;102:1476-1485.